Gujarat Themis Biosyn Merger & Restructuring
Gujarat Themis Biosyn Limited incorporated a wholly owned subsidiary, Themis Biosyn Japan Limited, in Japan. This strategic expansion marks the company's direct entry into the Japanese market.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
63 announcements with these filters
Gujarat Themis Biosyn Limited incorporated a wholly owned subsidiary, Themis Biosyn Japan Limited, in Japan. This strategic expansion marks the company's direct entry into the Japanese market.
Gujarat Themis Biosyn incorporated a wholly owned subsidiary in Japan named Themis Biosyn Japan Limited. This expansion strengthens the company's international pharmaceutical business footprint.
Gujarat Themis Biosyn scheduled a May 25, 2026 board meeting. Directors will consider FY26 audited financial results and recommend a potential equity dividend.